Browse Category

NYSE:LLY 28 January 2026 - 5 February 2026

For live price, interactive charts, financials and the latest market data, visit Google Finance.

Stock Market Today: S&P 500 futures steady after tech slump as Alphabet AI spending rattles investors

U.S. stock index futures showed a mixed picture early Thursday following a sharp tech sell-off. Nasdaq 100 futures ticked up 0.13%, while Dow futures fell 0.20%, and S&P 500 futures inched down 0.01%. These contracts trade before the cash market opens and often hint at Wall Street's initial direction.

5 February 2026

NASDAQ:AMD·NASDAQ:GOOGL·NYSE:LLY·Stock Market

Eli Lilly stock price jumps 10% after-hours on upbeat 2026 forecast and Q4 beat

Eli Lilly shares surged roughly 10.4% to $1,107.12 in after-hours trading Wednesday following a robust fourth-quarter report and a 2026 profit forecast that topped Wall Street estimates. During the regular session, the stock fluctuated between $995.88 and $1,114, with around 7.1 million shares changing hands.

4 February 2026

Earnings Reports·Financial Forecasts·NYSE:LLY

Eli Lilly stock jumps as 2026 forecast beats estimates on Zepbound, Mounjaro demand

Eli Lilly shares jumped roughly 9% on Wednesday, closing near $1,096 after hitting an intraday peak of $1,110.98. This gain stood out as the broader market slipped, with the SPY falling about 0.3% and the QQQ dropping close to 1.5%.

4 February 2026

Earnings Reports·NYSE:LLY·Pharmaceutical Industry·Stock Market

Novo Nordisk stock plunges as 2026 sales warning fuels price-war fears around Wegovy

Shares of Novo Nordisk plunged roughly 16% in Copenhagen on Wednesday after the Wegovy maker warned that sales and profits could dip in 2026 amid renewed pressure on U.S. drug prices. Jyske Bank analysts described the revised outlook as “yet another blow” for investors. In New York, the company’s ADRs dropped $1.94, or about 3.9%, to $48.36.

4 February 2026

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly (LLY) stock price jumps 10% after 2026 outlook; pricing pressure and FDA decision in focus

Eli Lilly and Company shares surged about 10% Wednesday after the company released its quarterly earnings and 2026 outlook, sparking renewed enthusiasm for its weight-loss division. The stock climbed to $1,104.94 in late-morning New York trading, bouncing back from a low of $995.88 earlier in the session.

4 February 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Dow Jones today: Dow edges higher as Lilly, Super Micro cushion Wall Street after AI software rout

The Dow Jones Industrial Average edged higher early on Wednesday, lifted by upbeat results from Eli Lilly and Super Micro Computer, while investors stayed cautious on software and cloud stocks after a sharp selloff a day earlier. At 09:30 a.m. ET, the Dow rose 175.92 points, or 0.40%, to 49,439.32; the S&P 500 was up 0.04% and the Nasdaq Composite fell 0.27%.

4 February 2026

NASDAQ:SMCI·NYSE:LLY·Stock Market

Eli Lilly stock in focus before earnings after Novo warns on obesity-drug price squeeze

Eli Lilly shares dipped slightly in premarket trading Wednesday, following a steep decline the day before that thrust the drugmaker back into focus in the obesity-drug sector. The stock was down roughly 0.5% at $998.50, after closing Tuesday at $1,003.21, slipping nearly 4%.

4 February 2026

Earnings Reports·NYSE:LLY·Pharmaceuticals·Stock Market

Eli Lilly stock price drops 4% as Novo outlook jars weight-loss trade ahead of earnings

Eli Lilly and Company shares dropped 3.9%, closing at $1,003.46 on Tuesday, then held steady in after-hours trading. Novo Nordisk’s U.S.-listed shares plunged 14%, after it forecast a steeper sales decline than expected for 2026, weighing on the obesity-drug sector. Pfizer also slipped following new weight-loss drug data. “Novo’s showing there’s a market for oral options,” noted Citizens analyst Jonathan Wolleben.

4 February 2026

Earnings Reports·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings

Shares of Eli Lilly and Company dropped 1.4% to $1,029.99 by midday Tuesday, sliding from a session peak of $1,048.71 and dipping as low as $1,016.15.

3 February 2026

Earnings Reports·NYSE:LLY·NYSE:NVO·NYSE:PFE·Pharmaceuticals·Stock Market

Eli Lilly stock price climbs as obesity-drug forecasts get a reality check before earnings

Shares of Eli Lilly and Company climbed roughly 1.5% on Monday, closing near $1,052.70, after fluctuating between $1,035.28 and $1,056.51 during the session.

2 February 2026

Earnings Reports·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly stock: LLY ends higher after $3.5 billion Pennsylvania plant plan as earnings near

Eli Lilly shares ended Friday up roughly 1.3%, closing at $1,037.15. The company unveiled a $3.5 billion initiative to boost U.S. manufacturing for its weight-loss business. Market data pegs the stock’s value at around $986 billion.

1 February 2026

Earnings Reports·NYSE:LLY·Pharmaceuticals·Stock Market

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Healthcare shares ended Friday stronger than the wider market following Eli Lilly’s announcement of a $3.5 billion manufacturing facility in Pennsylvania dedicated to injectable weight-loss drugs. CEO David Ricks described the new plant as “really state of the art manufacturing to last many decades to come” during a press briefing.

31 January 2026

HKG:1099·NYSE:AZN·NYSE:LLY·NYSE:MRK·NYSE:NVO·NYSE:PFE·Pharmaceuticals

Eli Lilly stock price (LLY): $3.5B plant, EU Mounjaro call and earnings ahead — what to watch

Shares of Eli Lilly finished Friday up about 1.3%, closing at $1,037.15. The boost came after the company unveiled a $3.5 billion plan for a new manufacturing facility in Pennsylvania. This plant will produce injectable weight-loss drugs, including retatrutide—a next-gen medication Lilly says has outperformed Zepbound. “All these sites, including this one, will be really state of the art manufacturing to last many decades to come,” CEO David Ricks said in Allentown. Drugmakers like Pfizer and Merck & Co are also expanding U.S. capacity amid Donald Trump’s threat of import tariffs. Meanwhile, Lilly is racing Novo Nordisk for U.S. approval of an oral weight-loss pill, which it plans to price at $150 a month and launch in several countries.

31 January 2026

Earnings Reports·NYSE:LLY·Pharmaceuticals·Stock Market

Eli Lilly stock climbs after $3.5 billion Pennsylvania plant plan as traders eye Feb. 4 results

Shares of Eli Lilly and Company climbed 1.3% to $1,037.15 in after-hours trading on Friday, following the announcement of a $3.5 billion manufacturing plant in Pennsylvania.During the session, the stock fluctuated between roughly $1,020 and $1,048.

31 January 2026

Earnings Reports·NYSE:LLY·Pharmaceuticals·Stock Market

Eli Lilly stock climbs after $3.5 billion Pennsylvania plant plan as investors eye earnings

Shares of Eli Lilly and Co climbed roughly 1.6% to $1,040.80 by midday Friday, following the announcement of a $3.5 billion injection drug manufacturing facility near Allentown, Pennsylvania. The S&P 500 edged down about 0.5%, while Novo Nordisk’s stock showed little movement.

30 January 2026

NYSE:LLY·Stock Market

Eli Lilly stock barely budges after $1.93bn autoimmune pact; Trump touts six U.S. plants

Eli Lilly shares ended little changed on Thursday after the drugmaker lined up another research collaboration, this time in autoimmune disease. The stock closed up 0.03% at $1,024.14, as Wall Street finished mixed.

30 January 2026

NYSE:LLY·Pharmaceuticals·Stock Market·US Economy

Eli Lilly stock price today: LLY rises on $1.93 billion Repertoire deal as earnings near

Eli Lilly shares climbed Thursday after Repertoire Immune Medicines announced a partnership with the drugmaker worth up to $1.93 billion, including an $85 million upfront payment, plus milestone and royalty fees. Lilly was up 0.5% at $1,028.89 in late morning trading, while the S&P 500 slipped about 1.4%. Repertoire will lead early research using its Decode platform, which explores how T cells attack diseased cells, before Lilly takes the programs to the clinic and eventually the market.

29 January 2026

Earnings Reports·NASDAQ:REPER·NYSE:LLY·Pharmaceuticals·Stock Market

Eli Lilly stock drops after hours: Medicare pricing talks and GLP-1 battle back in focus

Eli Lilly shares were down about 1.5% at $1,023.80 in after-hours trading on Wednesday, after swinging between $1,004.25 and $1,038.96 in the regular session.

29 January 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer shares dropped 1.8% to $26.02 in early afternoon trading, having fluctuated between $25.97 and $26.39.

28 January 2026

Earnings Reports·Healthcare News·NYSE:ABBV·NYSE:LLY·NYSE:PFE·Pharmaceuticals·Stock Market

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

Eli Lilly and Company shares dipped roughly 2.4% to $1,015.05 on Wednesday, following a close of $1,039.51 the day before. Intraday, the stock fluctuated between $1,012.09 and $1,038.96.

28 January 2026

Healthcare News·NYSE:LLY·Pharmaceuticals·Stock Market

Previous 1 2 3 4 5 6 … 14 Next

NYSE:LLY 28 January 2026 - 5 February 2026

Stock Market Today: S&P 500 futures steady after tech slump as Alphabet AI spending rattles investors

Eli Lilly stock price jumps 10% after-hours on upbeat 2026 forecast and Q4 beat

Eli Lilly stock jumps as 2026 forecast beats estimates on Zepbound, Mounjaro demand

Novo Nordisk stock plunges as 2026 sales warning fuels price-war fears around Wegovy

Eli Lilly (LLY) stock price jumps 10% after 2026 outlook; pricing pressure and FDA decision in focus

Dow Jones today: Dow edges higher as Lilly, Super Micro cushion Wall Street after AI software rout

Eli Lilly stock in focus before earnings after Novo warns on obesity-drug price squeeze

Eli Lilly stock price drops 4% as Novo outlook jars weight-loss trade ahead of earnings

Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings

Eli Lilly stock price climbs as obesity-drug forecasts get a reality check before earnings

Eli Lilly stock: LLY ends higher after $3.5 billion Pennsylvania plant plan as earnings near

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Eli Lilly stock price (LLY): $3.5B plant, EU Mounjaro call and earnings ahead — what to watch

Eli Lilly stock climbs after $3.5 billion Pennsylvania plant plan as traders eye Feb. 4 results

Eli Lilly stock climbs after $3.5 billion Pennsylvania plant plan as investors eye earnings

Eli Lilly stock barely budges after $1.93bn autoimmune pact; Trump touts six U.S. plants

Eli Lilly stock price today: LLY rises on $1.93 billion Repertoire deal as earnings near

Eli Lilly stock drops after hours: Medicare pricing talks and GLP-1 battle back in focus

Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

TechStock² Updates

T-Mobile Shares (TMUS) Inch Higher With Network Outage Searches Again Raising Questions Over Service Reliability

CBA posts all-time A$11 billion profit as credit costs surge 47%

NIQ shares surge 42% as improving cash flow reduces steep IPO discount

Disney Shares (DIS) Tick Up as Avengers Hype Confronts Profitability Challenge

QSR Stock Awaits Market Response as Tim Hortons Launches Harry Potter Menu After Flat Sales

Top Stock Picks

Taiwan Semiconductor

AerCap

Constellation Energy

Walt Disney

American International Group

Live updates

Investment Disclaimer